Laura Blair: Rethinking Hub Efficiency and the Role of AI in Patient Support

Key Takeaways

• Hub utilization sits at only 10‑15% despite heavy investment
• Design and access issues, not tech, drive low patient enrollment
• Simplifying regulatory steps could boost hub usage and outcomes
• AI handles routine queries but cannot replace empathetic human interaction
• Best AI use: augment staff with real‑time information and tools

Pulse Analysis

Specialty pharmaceutical companies have poured billions into patient‑support ecosystems—hubs, enrollment portals, and financial assistance programs—yet adoption remains stubbornly low. Industry data shows only about a tenth to a quarter of eligible patients actually navigate these tools, a shortfall Blair attributes to poor workflow design, redundant paperwork, and regulatory bottlenecks that overwhelm busy clinician offices. When a patient must secure a live signature or wrestle with a confusing form, the friction often aborts the treatment journey before therapy even begins, inflating acquisition costs and delaying revenue streams.

Artificial intelligence offers a tempting shortcut, but Blair cautions against overreliance. Bots excel at answering straightforward, transactional questions—such as eligibility checks or dosage schedules—but they falter when patients are newly diagnosed, frightened, or facing complex financial decisions. The emotional nuance required in those moments demands human empathy, active listening, and the ability to pause and clarify. By positioning AI as a decision‑support layer—providing agents with real‑time patient data, suggested scripts, and compliance guidance—pharma firms can preserve the human touch while accelerating response times and reducing administrative burden.

The strategic implication for the sector is clear: redesign hub entry points to eliminate unnecessary steps, streamline legal and regulatory requirements, and deploy AI as an augmentation tool rather than a replacement. Companies that invest in user‑centric interfaces and equip their support staff with intelligent assistants are likely to see higher utilization rates, faster time‑to‑therapy, and stronger patient loyalty, ultimately translating into improved market share and profitability.